GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update
February 23 2022 - 9:00AM
via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a
biotechnology company developing immunotherapies and vaccines
against infectious diseases and cancer, announces today that it
will report 2021 financial results on Wednesday, March 9, 2022
after the market closes.
Management will host a conference call at 4:30
p.m. ET on Wednesday, March 9, 2022 to review financial results and
provide an update on corporate developments. Following management’s
formal remarks, there will be a question-and-answer session.
Participants are asked to pre-register for the
call via the following link:
https://dpregister.com/sreg/10164185/f1aa6acaf6
Please note that registered participants will
receive their dial-in number upon registration and will dial
directly into the call without delay. Those without Internet access
or who are unable to pre-register may dial in by calling
1-866-777-2509 (domestic) or 1-412-317-5413 (international). All
callers should dial in approximately 10 minutes prior to the
scheduled start time and ask to be joined into the GeoVax Labs
call.
The conference call will be available through a
live webcast found here:
https://services.choruscall.com/mediaframe/webcast.html?webcastid=liKBkNK2
A webcast replay of the call will be available via
the same link as the live webcast approximately one hour after the
end of the call through June 9, 2022. A telephonic replay of the
call can be accessed by calling 1-877-344-7529 (domestic) or
1-412-317-0088 (international) and using access code 3389318. The
telephonic replay will be available until March 23, 2022.
About GeoVax
GeoVax Labs, Inc. is a clinical-stage
biotechnology company developing human vaccines and immunotherapies
against infectious diseases and cancer using novel proprietary
platforms. GeoVax’s product pipeline includes two ongoing Phase 2
clinical trials of GEO-CM04S1 (formerly COH04S1) for COVID-19 as a
universal booster vaccine to mRNA vaccines authorized by the U.S.
Food and Drug Administration (FDA) and as a primary vaccine for use
in immunocompromised patients. In addition to GEO-CM04S1 for
COVID-19, GeoVax is developing GEO-CM02 as a pan-coronavirus
vaccine. The Company is also conducting a Phase 1/2 clinical trial
of Gedeptin® for treatment of head and neck cancer. Gedeptin® has
been granted orphan drug status by the FDA. Additional research and
development programs include preventive vaccines against Zika
Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa)
and malaria, as well as immunotherapies for multiple solid tumors.
The Company’s portfolio of wholly owned, co-owned, and in-licensed
intellectual property stands at over 70 granted or pending patent
applications spread over 20 patent families.
For additional information about GeoVax, visit our
website: www.geovax.com.
GeoVax Labs,
Inc.678-384-7220investor@geovax.com
GeoVax Labs (NASDAQ:GOVXW)
Historical Stock Chart
From Sep 2024 to Oct 2024
GeoVax Labs (NASDAQ:GOVXW)
Historical Stock Chart
From Oct 2023 to Oct 2024